<DOC>
	<DOC>NCT02261285</DOC>
	<brief_summary>The objective of the study is to investigate the pharmacokinetics of ONO-4538 administered to Korean patients with advanced or recurrent solid tumors who are refractory or intolerant to standard therapy or for whom no appropriate treatment is available.</brief_summary>
	<brief_title>ONO-4538 Phase I Study in Patients With Solid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Male or female â‰¥ 20 years of age Histologically or cytologically confirmed solid tumor Patients with advanced or recurrent solid tumors who are refractory or intolerant to standard therapy or for whom no appropriate treatment is available ECOG Performance Status is 0 to 1 Current or prior severe hypersensitivity to another antibody product Multiple primary cancers</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>